智通财经APP获悉，派格生物医药-B(02565)再涨超15%，高见37港元再创上市新高。截至发稿，涨14.5%，报36.64港元，成交额2599.96万港元。
消息面上，近日诺和诺德司美格鲁肽获批MASH新适应症，引发GLP-1板块热度。公开资料显示，派格生物医药是一家专注于自主研究及开发慢性病创新疗法的生物技术公司，旗下共有6款在研药物，其中有4条管线与GLP-1类药物相关，适应症几乎都是针对肥胖、超重、糖尿病等领域。目前公司最有希望商业化的产品PB-119，是GLP-1受体激动剂，用于减重领域。
智通财经APP在《银诺医药-B(02591)暗盘暴涨270%引市场聚焦GLP-1赛道，派格生物医药-B(02565)价值洼地增长可期》中指出，从市场角度来看，中国作为全球第二大医药市场，同时拥有全球最大规模的糖尿病(预计2030年达1.64亿人)和超重人群(预计2030年达2亿至2.5亿人)，已成为全球制药巨头与本土企业争夺的关键战略高地。随着市场潜力的持续释放，派格生物有望凭借差异化创新能力以及具备BIC属性的核心品种维培那肽重塑国内T2DM治疗市场格局，加速释放自身内在价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.